Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

0.4981
+0.03938.57%
Pre-market: 0.4900-0.0081-1.63%08:00 EST
Volume:259.84K
Turnover:128.34K
Market Cap:9.29M
PE:-0.83
High:0.5174
Open:0.4670
Low:0.4601
Close:0.4588
52wk High:3.28
52wk Low:0.3679
Shares:18.65M
Float Shares:15.47M
Volume Ratio:1.25
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5992
EPS(LYR):-0.8255
ROE:-178.46%
ROA:-106.58%
PB:1.95
PE(LYR):-0.60

Loading ...

Should You Think About Buying Nuix Limited (ASX:NXL) Now?

Simply Wall St.
·
Feb 13

Nexalin Technology Partners with UC San Diego to Launch AI-Driven NeuroCare Virtual Clinic

Reuters
·
Feb 05

Nexalin Technology highlights research validating neurostimulation technology

TIPRANKS
·
Feb 02

RBC Capital Reaffirms Their Hold Rating on Nuix Ltd. (NXL)

TIPRANKS
·
Jan 31

BRIEF-Nexalin Technology Receives Nasdaq Listing Status Notification

Reuters
·
Jan 24

Nexalin Technology Neurostimulation Device Shows Significant ADHD Symptom Improvement in Clinical Study

Reuters
·
Jan 14

Nexalin Advances Non-Invasive Alzheimer's Therapy Toward FDA Clinical Trials

Reuters
·
Dec 03, 2025

BRIEF-Nexalin Technology Completes FDA Q-Submission Meeting For Gen-2 Sync

Reuters
·
Dec 03, 2025

Nexalin Technology Inc - Potential De Novo Pathway Discussed for Nexalin's Technology

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Inc - Reviewed Endpoints for Alzheimer's Outcomes Including Cognitive Assessments

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Inc - Plans U.S. Pilot and Pivotal Studies for Gen-2 Sync

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 Sync™ Neurostimulation Console in Alzheimer’s Disease Program

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Inc: Intends to Incorporate FDA's Feedback From Q-Sub Meeting Into Its Final Pilot Study Protocol

THOMSON REUTERS
·
Dec 03, 2025

Nexalin Technology Hosts Live Investor Webinar Showcasing Mental Health Innovations

Reuters
·
Dec 02, 2025

Nuix (ASX:NXL) delivers shareholders solid 39% CAGR over 3 years, surging 12% in the last week alone

Simply Wall St.
·
Nov 29, 2025

Morgan Stanley Sticks to Their Buy Rating for Nuix Ltd. (NXL)

TIPRANKS
·
Nov 20, 2025

Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders

Reuters
·
Nov 18, 2025

Nexalin Technology Faces Financial Risks Amid U.S.-China Trade Tensions

TIPRANKS
·
Nov 15, 2025

Nexalin Technology Secures Exclusive Distribution Agreement With Carmi Masha in Israel

Reuters
·
Nov 13, 2025

Nuix Limited (ASX:NXL) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

Simply Wall St.
·
Nov 08, 2025